We are live on ! Find out more
PBE icon

Invesco Biotechnology & Genome ETF

70 hedge funds and large institutions have $116M invested in Invesco Biotechnology & Genome ETF in 2014 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 20 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% more capital invested

Capital invested by funds: $113M → $116M (+$2.43M)

0.52% less ownership

Funds ownership: 29.56%29.04% (-0.52%)

5% less funds holding

Funds holding: 7470 (-4)

10% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 20

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

Holders
70
Holders Change
-4
Holders Change %
-5.41%
% of All Funds
2.03%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
18
Reduced
20
Closed
11
Calls
Puts
Net Calls
Net Calls Change

PBE Hedge Fund Activity: Q3 2014 in Review

70 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q3 2014, worth a combined $116M — up 2.1% from $113M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of PBE and 7 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 18 added.

The largest buyer was Baldwin Wealth Partners, opening a new position worth an estimated $1.49M. The largest seller was Morgan Stanley, cutting an estimated $1.62M.

  • 70 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q3 2014, down from 74 in Q2 2014.
  • Funds reported $116M of Invesco Biotechnology & Genome ETF stock for Q3 2014, up 2.1% quarter-over-quarter.
  • 7 funds opened new Invesco Biotechnology & Genome ETF positions in Q3 2014 and 11 closed out, a net change of -4 holders.
  • The largest Invesco Biotechnology & Genome ETF buyer in Q3 2014 was Baldwin Wealth Partners, an estimated $1.49M added.
  • The largest Invesco Biotechnology & Genome ETF seller in Q3 2014 was Morgan Stanley, an estimated $1.62M sold.

Based on aggregated 13F filings for Q3 2014.